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Background. Healthcare-associated infections (HAIs) remain a significant patient safety issue, with point prevalence estimates 
being ~5% in high-income countries. In 2016–2017, the Researching Effective Approaches to Cleaning in Hospitals (REACH) study 
implemented an environmental cleaning bundle targeting communication, staff training, improved cleaning technique, product use, 
and audit of frequent touch-point cleaning. This study evaluates the cost-effectiveness of the environmental cleaning bundle for re-
ducing the incidence of HAIs.
Methods. A stepped-wedge, cluster-randomized trial was conducted in 11 hospitals recruited from 6 Australian states and ter-
ritories. Bundle effectiveness was measured by the numbers of Staphylococcus aureus bacteremia, Clostridium difficile infection, and 
vancomycin-resistant enterococci infections prevented in the intervention phase based on estimated reductions in the relative risk 
of infection. Changes to costs were defined as the cost of implementing the bundle minus cost savings from fewer infections. Health 
benefits gained from fewer infections were measured in quality-adjusted life-years (QALYs). Cost-effectiveness was evaluated using the 
incremental cost-effectiveness ratio and net monetary benefit of adopting the cleaning bundle over existing hospital cleaning practices.
Results. Implementing the cleaning bundle cost $349 000 Australian dollars (AUD) and generated AUD$147 500 in cost savings. 
Infections prevented under the cleaning bundle returned a net monetary benefit of AUD$1.02 million and an incremental cost-ef-
fectiveness ratio of $4684 per QALY gained. There was an 86% chance that the bundle was cost-effective compared with existing 
hospital cleaning practices.
Conclusions. A bundled, evidence-based approach to improving hospital cleaning is a cost-effective intervention for reducing 
the incidence of HAIs.
Keywords.  cost-effectiveness; infection control; healthcare-associated infections; environmental cleaning; hospital.
Infection-control programs deliver evidence-based strategies 
aimed at preventing healthcare-associated infections (HAIs) 
[1]. Improving hand hygiene compliance [2], healthcare worker 
education [3], and optimal clinical practice bundles [4] has 
been effective in reducing HAI burden, resulting in cost sav-
ings for health services and health benefits for patients [5]. 
Nonetheless, HAIs remain a significant patient safety issue, with 
point prevalence estimates being approximately 5% in high-
income countries [6, 7].
Environmental cleaning is an important element of an 
infection-control program [8]. Pathogens responsible for HAIs 
survive on surfaces for many months [9], increasing the risk of 
patient acquisition [10]. To date, evaluations of environmental 
cleaning have been limited to the management of outbreaks or 
quasi-experimental studies [11]. However, growing evidence 
supporting the link between environmental contamination and 
pathogen transmission [12] has motivated research into the im-
pact of improving routine cleaning practices on HAI rates [13].
In 2016–2017, the Researching Effective Approaches to 
Cleaning in Hospitals (REACH) study evaluated an environ-
mental cleaning bundle for reducing HAI rates in 11 Australian 
hospitals [14]. The bundle implemented 5 interventions targeted 
at improving cleaning practices, which emphasized engagement 
with environmental services staff. Bundle effectiveness was 
measured by improvements in frequent touch-point cleaning 
and rate reductions in Clostridium difficile infection (CDI), 
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Staphylococcus aureus bacteremia (SAB), and vancomycin-
resistant enterococci (VRE) infection.
Investment in new infection-control initiatives redirects 
scarce resources from competing programs [15]. The eco-
nomic returns of new programs should ideally exceed those 
for programs that are displaced, and cost-effectiveness anal-
ysis is useful for deciding which programs should be sup-
ported. In this paper, we evaluate the cost-effectiveness of 
the REACH cleaning bundle. Our analysis considered the 
costs of implementing the bundle, expected cost savings 
from fewer infections, and changes to health outcomes. 
The results are intended to inform hospital decision makers 
about whether to adopt the cleaning bundle as part of a 
hospitalwide infection-control program. Methods and out-
comes are reported in accordance with the Consolidated 
Health Economic Reporting Standards (CHEERS) statement 
(Supplementary File 1).
METHODS
Setting and Study Design
Eleven hospitals participated in the REACH study, representing 
over 1700 environmental services staff and 6100 overnight beds 
in large public and private hospitals. All hospitals had an es-
tablished HAI surveillance program in place before enrollment, 
which included data collection on healthcare-associated CDI, 
SAB, and VRE infections [14, 16].
The intervention was an environmental cleaning bundle 
with 5 evidence-based components targeting audit, commu-
nication, technique, training, and product [14]. A full descrip-
tion of each bundle component is provided in Supplementary 
File 2. The bundle was implemented in all hospitals using a 
stepped-wedge cluster-randomized design, with interven-
tion timings randomized after all hospitals were enrolled. 
Before switching to the intervention, hospitals completed 
a 4-week establishment and an 8-week control period. The 
length of the intervention varied between 20 and 50 weeks, 
with an average length of 35 weeks. The design allowed all 
hospitals to receive the intervention, with each acting as its 
own control. The sequential roll-out of the bundle maximized 
the feasibility and consistency of implementation across 
sites, allowing researchers to work with individual hospitals. 
Given baseline differences between hospitals in cleaning 
practices [17], a pragmatic approach to implementation was 
taken, which allowed the bundle to be tailored to individual 
hospitals based on changes required to meet best-practice 
cleaning guidelines.
Ethics approval for the REACH study was obtained locally 
from all participating hospitals, the Uniting Health Human 
Research Ethics Committee (approval number 1413), and the 
Queensland University of Technology Human Research Ethics 
Committee (approval number 1400000828).
Analysis
We evaluated the cost-effectiveness of the intervention over 
current hospital cleaning practices using data collected along-
side the REACH study. Changes to costs reflected the health-
care system perspective and were defined as the cost of bundle 
implementation minus cost savings from modeled reductions 
in infection rates. Changes to health benefits were measured 
in quality-adjusted life-years (QALYs). Cost-effectiveness was 
evaluated over 62 weeks, from the start of the establishment pe-
riod in the first hospital until the end of the study.
Implementation costs covered the purchase of consum-
ables and the value of staff time spent on bundle activities. 
Consumables were valued using unit costs and included pro-
motional and training materials, audit equipment, and disin-
fectant for frequent touch-point cleaning. Staffing costs were 
based on time contributions from hospital management and 
environmental services staff and were valued using wage rates. 
Costs were valued in 2016 Australian dollars. No discounting 
was applied for time preferences given the short time horizon. 
Further details are in Supplementary File 3.
Total implementation costs were organized by bundle com-
ponent for preintervention (establishment/control) and inter-
vention phases (Supplementary Table 1). This allowed us to 
estimate the costs of establishing and maintaining the bundle 
and the relative contribution of different components. Expected 
per-hospital costs were calculated to inform on the implementa-
tion costs at a future site, accounting for differences in interven-
tion length, occupied bed days, and numbers of environmental 
services staff employed.
Bundle effectiveness was modeled using hospital surveillance 
data collected between May 2015 and July 2017 [16]. Statistical 
models estimated the expected within-hospital change in infec-
tion rates per 10 000 occupied bed days from the intervention 
and were fitted separately to each infection. Models accounted 
for between-hospital differences in preintervention rates and 
included a linear time trend to capture pre-existing trends. 
Effectiveness was modeled by a binary step change, which 
started after the first 4 weeks of the intervention phase to ac-
count for an initial leaning period. For infections where the rel-
ative risk of the intervention was less than 1, model parameters 
were used to estimate the number of infections prevented under 
the intervention.
Cost savings were measured by the value of bed days released 
and treatment costs avoided (Table 1). Excess length-of-stay es-
timates were sourced from studies identified by systematic re-
views [18, 19]. Where possible, we used separate estimates for 
the general ward and intensive care unit (ICU) and for different 
patient outcomes (died in hospital or discharged). The eco-
nomic value of total bed days released was determined using 
2 approaches representing different healthcare payer perspec-
tives. The first approach was based on an Australian hospital 
chief executive officer’s (CEO’s) stated willingness to pay (WTP) 
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for a bed day to reflect the perspective of the hospital decision 
maker [20]. The second approach considered the accounting 
value of a hospital bed day based on historical spending. 
Accounting estimates were calculated using reported recurrent 
expenditure on admitted care and patient days in Australian 
public hospitals [21, 29]. Dollar values were adjusted to 2016 
Australian dollars to account for inflation in healthcare expend-
iture [22]. Treatment costs covered diagnostic testing and anti-
biotics [23, 24] following consultation with infectious disease 
experts. Vancomycin-resistant enterococci treatment costs were 
estimated by the weighted average of costs for treating blood-
stream and urinary tract infections, as these accounted for 98% 
of reported preintervention infections.
Out of the number of infections prevented, we assumed 
that a proportion of patients would have died due to infection. 
Mortality risks were sourced from the same studies identified 
for extra length of stay if available (Table 1). Total years of life 
gained were calculated as the difference between the average age 
of infected patients and life expectancies at the time of infec-
tion [27]. Years of life gained were converted to QALYs using 
age-group–specific health utilities measured in the Australian 
general population [29]. Total QALYs were discounted by 3% 
per annum to reflect the reduced future value of health benefits 
[31].
The cost-effectiveness of the intervention was evaluated 
using the incremental cost-effectiveness ratio (ICER) and net 
monetary benefit (NMB), which offered different summaries of 
the change in costs versus health benefits. The ICER reports the 
incremental cost per QALY gained, which is compared with a 
maximum WTP per QALY:
Table 1. Parameter Estimates and Prior Distributions for Evaluating the Cost-effectiveness of the Cleaning Bundle
Parameter Estimate Prior Distribution
Staphylococcus aureus bacteremia
 Log infection rate per 10 000 occupied bed days, pre-intervention −0.03 Normal (−0.03,0.13)
 Log relative risk, intervention −0.20 Normal (−0.20, 0.16)
 Excess length of stay from infection, days [25] 12.7 (general ward, discharged) Normal (12.7, 2.2)
−1.5 (general ward, died) Normal (−1.5, 3.3)
0.9 (ICU, discharged) Normal (0.9, 0.7)
1.4 (ICU, died) Normal (1.4, 0.6)
 Treatment costs per infection [23, 24] $1017 Fixed
 Probability of death [25] 0.06 (not infected) Beta (175, 2775)
0.17 (infected) Beta (124, 620)
 Average patient age [26], years 62 Fixed
 Life expectancy at time of infection, years [27] 25.0 (female); 22.1 (male) Fixed
VRE infection
 Log infection rate per 10 000 occupied bed days, preintervention −1.0 Normal (−1.0, 0.46)
 Log relative risk, intervention −0.46 Normal (−0.46, 0.14)
 Excess length of stay from infection, days [18] 3.8 Uniform (3.0, 4.6)
 Mortality risk [28] 0.07 (not infected) Beta (35, 497)
0.10 (infected) Beta (52, 480)
 Treatment costs per infection [23] $1708 (BSI); $844 (UTI) Fixed
 Log odds of VRE BSI vs VRE UTIa 0.38 Normal (−0.49, 0.42)
 Average patient age [28], years 66 Fixed
 Life expectancy at time of infection, years [27] 21.5 (female); 18.9 (male) Fixed
Clostridium difficile infection
 Log infection rate per 10 000 occupied bed days, preintervention 0.85 Normal (0.85, 0.21)
 Log relative risk, interventionb 0.07 Normal (0.07, 0.10)
Health benefits
 Health utilities, Australian norms [29] 0.80 (75+ years) Beta (546,136)
0.82 (65–74 years) Beta (2066, 594)
Dollar value per bed day released
 Willingness to pay [20, 22] $284 (general ward) Normal (284, 23)
$573 (ICU) Normal (573, 86)
 Accounting cost [21, 30] $1667 (general ward); $6280 (ICU) Fixed
Abbreviations: BSI, bloodstream infection; ICU, intensive care unit; REACH, Researching Effective Approaches to Cleaning in Hospitals; UTI, urinary tract infection; VRE, vancomycin-resistant 
enterococci.
aDetermined from REACH study data.
bInsufficient evidence of bundle effectiveness to assign cost savings and health benefits.
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ICER =
Change in costs
Change in QALYs
In contrast, NMB is a rearrangement of the ICER that summar-
izes the difference between the economic value of health bene-
fits and the change in costs:
NMB = (WTP× Change in QALYs)− Change in costs
Interventions with a positive NMB or an ICER less than the 
chosen WTP threshold are cost-effective. Our analysis used a 
WTP threshold of $28 000/QALY, which reflected the oppor-
tunity cost of additional healthcare expenditures under a con-
strained budget [32].
Probabilistic sensitivity analysis was undertaken to account 
for uncertainty in model parameters and its impact on cost-ef-
fectiveness outcomes. Selected prior distributions characterized 
uncertainty in bundle effectiveness, literature-based param-
eters, and hospital costs (Table 1). Uncertainty in staff time costs 
was modeled using uniform distributions by staff role, defined 
by minimum and maximum hourly rates. Uniform distribu-
tions were also used to add a 10% margin of error to weekly 
incremental costs for disinfectant to reflect the likelihood that 
hospitalwide changes in product use were not exclusively driven 
by recommended changes in frequent touch-point cleaning. 
Outcomes from sensitivity analyses were based on 10 000 simu-
lations. Given issues with interpreting uncertainty in the ICER 
[33], the probability that the intervention was cost-effective was 
calculated as the proportion of model simulations that returned 
a positive NMB.
RESULTS
REACH Bundle Effectiveness
The intervention was associated with a decrease in SAB and 
VRE infection rates, with a combined 40 infections prevented 
over approximately 1.3 million occupied bed days. Bundle ef-
fectiveness estimates were larger for SAB (23.5 infections pre-
vented; 95% confidence interval [CI], −15.3 to 62.0) compared 
with VRE (16.0 infections prevented; 95% CI, 0.1–32.1); how-
ever, the former had greater statistical uncertainty. Insufficient 
evidence of effectiveness on CDI rates (relative risk, 1.07; 95% 
CI, 0.88–1.30) led to its exclusion from subsequent analysis, 
given our focus on cost savings and health benefits from fewer 
infections. Infections prevented under the intervention resulted 
in a combined gain of 43 QALYs (95% CI, −17.8 to 160.5).
Cost Outcomes
Implementing the cleaning bundle cost approximately $349 000 
(95% CI, $331 000–$367 000), or $2430 per 10 000 occupied 
bed days during the intervention phase (Figure 1). Changing 
disinfectant represented 34% of total costs ($118 000; 95% CI, 
$107  000–$129  000) or $823 per 10  000 occupied bed days. 
Preintervention audit activities and study-related implemen-
tation incurred similar costs; however, their overall contribu-
tion was relatively small, consuming 15% of total costs. After 
accounting for differences in occupied bed days, the expected 
per-hospital costs of establishing and maintaining the cleaning 
bundle were approximately $4960 (95% CI, $4700–$5200) and 
$29  400 (95% CI, $27  700–$31  000), respectively. Hospital-
level disinfectant costs were a key source of heterogeneity 
between hospitals, ranging from $838 saved to an additional 
$3090 spent per 10  000 intervention-occupied bed days. 
A  further breakdown of costs is provided in Supplementary 
Tables 2 and 3.
Fewer infections during the intervention phase released 346 
bed days and generated $147  000 in savings under the CEO 
WTP approach to valuing bed days (Table 2). Approximately 
one-third of savings were from treatments avoided, with cost 
savings marginally higher for SAB ($23 900; 95% CI, −$16 000 
to $63  000) compared with VRE ($18  800; 95% CI, $125–
$38 000). Total savings based on accounting values were higher, 
resulting in a net cost saving of $375 000 (95% CI, -$1 486 000 
to $605 000). Because extra length-of-stay estimates for VRE 
were not available separately for the general ward and the ICU, 
our analysis assumed cost savings for this infection based on 
general ward values only. A follow-up analysis of this assump-
tion and its impact on expected cost savings is provided in 
Supplementary Table 4.
There was strong evidence that the intervention was cost-ef-
fective; however, outcomes were affected by the approach 
taken for valuing bed days (Figure 2). Under the conservative 
CEO WTP approach, the NMB of the cleaning bundle was 
0 5 10 15 20 25 30 35
Communication
Study related
Audit
Training
Product
$0 $20,000 $40,000 $60,000 $80,000 $100,000 $120,000
Contribution to trial cost (%)
Total costs incurred (AUD)
Figure 1. Summary of total trial costs across all hospitals by phase and bundle 
component. Estimates are expected values from 10  000 model simulations. 
Gray = preintervention; black = intervention. Abbreviation: AUD, Australian dollars.
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approximately $1.02 million, with an expected ICER of $4684 
per QALY. In contrast, higher dollar values assigned to ge-
neral ward and ICU bed days under the accounting approach 
returned a NMB of $1.6 million and an expected savings of 
$8685 per QALY. Despite these differences, the probability 
that the intervention was cost-effective was consistently high, 
with 86% and 88% of model simulations returning a pos-
itive NMB under CEO WTP and accounting approaches, 
respectively.
DISCUSSION
Our study has shown that the REACH cleaning bundle is likely 
to be a cost-effective intervention for reducing HAI burden. 
Using data collected from a representative mix of Australian 
hospitals, adopting the bundle cost $4684 per QALY and had 
greater than an 80% chance of being cost-effective. Pragmatic 
implementation of the bundle in real-world hospital settings 
combined with prospective data collection under a stepped-
wedge design produced high-quality evidence that the bundle 
would be cost-effective if implemented elsewhere in similar 
hospitals for reducing healthcare-associated SAB and VRE 
infections.
Differences between approaches to valuing bed days high-
lighted the importance of healthcare payer perspective and its 
impact on decision making. While cost-effectiveness probabil-
ities were robust, the use of accounting values predicted net cost 
savings from fewer SAB and VRE infections. Unlike resources 
such as antibiotics that incur direct expenditure, bed days are an 
opportunity cost of treating an HAI [34], and their release for 
use by other patients does not result in immediate cash savings 
[15]. As the outcomes of cost-effectiveness analysis are intended 
to inform decisions about the reallocation of scarce resources, 
the WTP approach is recommended to avoid overstating ex-
pected savings from proposed interventions.
Insufficient evidence of the bundle in reducing CDI rates 
led to its exclusion from analysis. We have no plausible reason 
to believe that the intervention increased CDI rates, as it was 
implemented alongside ongoing infection-control activities. 
A possible explanation for this result is the impact of CDI reser-
voirs in the community and subsequent transmission of geneti-
cally diverse strains into the hospital setting [35]. Furthermore, 
not all hospitals used a sporicidal disinfectant [17] and, because 
the bundle did not prescribe specific cleaning products, it is 
likely that some products used were ineffective against CDI.
Costing information sought to inform on real-world imple-
mentation costs but was subject to limitations. Low-quality 
data on detergent use led to their exclusion from analysis; 
however, the effect of this was likely to be small as practice 
changes predominantly involved increased disinfectant use 
for frequent touch-point cleaning. Furthermore, costs were 
not attributed to improving cleaning technique as this would 
have required time-in-motion studies. Instead, we assumed 
that the number of cleaning staff within a hospital did not 
change, and that staff would be cleaning more effectively due 
to improved product use and cleaning technique. No major 
changes to staffing were reported as part of routine moni-
toring throughout the study.
Cost savings relied on secondary data sources for extra 
length of stay and infection-related mortality. Outcomes from 
multistate modeling studies were used for SAB to minimize the 
risk of time-dependent bias [19, 36, 37]; however, similar studies 
for VRE infection were unavailable. Vancomycin-resistant en-
terococci estimates were sourced from studies with comparable 
patient infection case mix and were comparable with other 
HAI studies [38, 39]. Future studies of VRE outcomes should 
Table 2. Estimated Cost Savings From Fewer Staphylococcus aureus bacteremia and vancomycin-resistant enterococci Infections
Estimate (95% CI)
Outcome SAB VRE
Bed days released  
 General Ward 263 (−162 to 751) 61 (−.1 to 127)
 ICU 22 (−18 to 89) …
Dollar value of bed days released   
 Accounting $579 507 (−$346 131 to $1 647 934) $101 404 ($652 to $210 925)
 CEO WTP $87 547 (−$54 856 to $246 323) $17 272 ($110 to $36 498)
Treatment costs avoided $23 884 (−$15 537 to $63 109) $18 814 ($125 to $38 255)
 Accounting $25 721 ($15 481 to $36 082) $7508 ($6226 to $8795)
 CEO WTP $4749 ($3342 to $6249) $2254 ($1927 to $2603)
Change in total costs
 Accounting −$374 708 (−$1 485 578 to $605 129)
 CEO WTP $201 398 ($4507 to $385 570)
Abbreviations: CI, confidence interval; ICU, intensive care unit; CEO, chief executive officer; SAB, Staphylococcus aureus bacteremia; VRE, vancomycin-resistant enterococci; WTP, willing-
ness to pay.
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prioritize the use of multistate modeling to address this limita-
tion and the differential effects of bloodstream versus urinary 
tract infection.
Treatment costs per infection were based on expert opinion 
and are a potential limitation of our model. However, resulting 
cost savings were conservative compared with other studies. 
For example, a retrospective cohort analysis on the costs of 
SAB-related hospitalizations between 2010 and 2014 reported 
estimates of US$15  578–$40  725 for methicillin-susceptible 
Staphylococcus aureus and US$14 792–$34 526 for methicillin-
resistant S. aureus [40]. Attributable costs per VRE infection of 
US$6565–$14 850 have also been published [41, 42].
It is possible that a Hawthorne effect contributed to bundle 
effectiveness outcomes, as hospital staff were likely to change 
behavior because they were being monitored. Given the inclu-
sion of monthly audits as a fixed element of the bundle, such an 
effect can be considered as part of the bundle as staff were likely 
to change their behavior precisely because they were being 
monitored.
Findings from this study compare favorably against other 
HAI prevention strategies and provide evidence for allocating 
hospital resources to improving cleaning. In the United 
States, a 10-year study of investment in infection-prevention 
measures produced an ICER of US$23 278 (AUD$31 457; 1 
AUD  =  0.74 USD) per QALY based on reductions in cen-
tral line–associated bloodstream infections and ventilator-
associated pneumonia [5]. A retrospective evaluation of the 
Australian National Hand Hygiene Initiative reported sim-
ilar outcomes for SAB, with an incremental program cost of 
AUD$29  700 per QALY [26]. While this comparison raises 
questions about disinvestment from more expensive preven-
tion strategies, we stress that our analysis describes the incre-
mental cost-effectiveness of improved cleaning conditional 
on existing measures. Decision makers should therefore con-
sider these results in the context of current hospital practices 
and the relative effectiveness of current infection-control 
measures.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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Figure 2. Cost-effectiveness plane (top panel). Distribution of NMB (bottom panel). Outcomes are colored according to the approach for valuing hospital bed days 
(gray = accounting; black = CEO willingness to pay). Abbreviations: AUD, Australian dollars; CEO, chief executive officer; NMB, net monetary benefit; Pr, probability; QALY, 
quality-adjusted life-year.
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